SHAREHOLDER ALERT: CCIV PCT PRVB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / July 5, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Churchill Capital Corp IV (NYSE:CCIV)
If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/churchill-capital-corp-iv-loss-submission-form?prid=17394&wire=1
Lead Plaintiff Deadline: August 30, 2021
Class Period: January 11, 2021 - February 22, 2021
Allegations against CCIV include that: (1) Lucid was not prepared to deliver vehicles by spring of 2021; (2) Lucid was projecting a production of 557 vehicles in 2021 instead of the 6,000 vehicles touted in the run-up to the merger with Churchill; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
PureCycle Technologies, Inc. (NASDAQ:PCT)
If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/purecycle-technologies-inc-loss-submission-form?prid=17394&wire=1
Lead Plaintiff Deadline: July 12, 2021
Class Period: November 16, 2020 - May 5, 2021
Allegations against PCT include that: (i) the technology PureCycle licensed from Procter & Gamble is not proven and presents serious issues even at lab scale; (ii) the challenges posed by the availability and competition for the raw materials necessary to commercialize the licensed technology are significant; (iii) PureCycle's financial projections are baseless; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Provention Bio, Inc. (NASDAQ: PRVB)
If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/provention-bio-inc-loss-submission-form?prid=17394&wire=1
Lead Plaintiff Deadline: July 20, 2021
Class Period: November 2, 2020 - April 8, 2021
Allegations against PRVB include that: (i) the teplizumab Biologics License Application ("BLA") was deficient in its submitted form and would require additional data to secure U.S. Food and Drug Administration approval; (ii) accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed; (iii) the Company had thus overstated the teplizumab BLA's approval prospects and hence the commercialization timeline for teplizumab; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com:
https://www.accesswire.com/654259/SHAREHOLDER-ALERT-CCIV-PCT-PRVB-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines
